Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

Benzinga · 2d ago
Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.